Jump to main content
Jump to site search

Issue 21, 2009
Previous Article Next Article

Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFRtyrosine kinase

Author affiliations

Abstract

Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFRtyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain. Among the compounds synthesized, compounds 6c, 7b, and 7d reduced the EGF-mediated phosphorylation of EGFRtyrosine kinase and its downstream kinases including ERK and Akt in A431 cells. The cell growth was inhibited by these compounds through arrest of G1 cell cycle, which induced apoptosis. A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compound 7d against EGFRtyrosine kinase. Quantum mechanical docking simulation revealed that the boronic acid moiety of compound 7d formed a covalent B–O bond with Asp800 in addition to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compound 7d toward EGFRtyrosine kinase.

Graphical abstract: Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFRtyrosine kinase

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 May 2009, accepted on 15 Jul 2009 and first published on 20 Aug 2009


Article type: Paper
DOI: 10.1039/B909504G
Citation: Org. Biomol. Chem., 2009,7, 4415-4427
  •   Request permissions

    Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFRtyrosine kinase

    H. S. Ban, T. Usui, W. Nabeyama, H. Morita, K. Fukuzawa and H. Nakamura, Org. Biomol. Chem., 2009, 7, 4415
    DOI: 10.1039/B909504G

Search articles by author

Spotlight

Advertisements